ReviewSeminars in immunopathology2013
Experimental models and therapeutic approaches for HBV.
Review in Seminars in immunopathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Review
- The Role of Infected Cell Proliferation in the Clearance of Acute HBV Infection in Humans.Viruses · 2017Article
- T cell--associated immunoregulation and antiviral effect of oxymatrine in hydrodynamic injection HBV mouse model.Acta pharmaceutica Sinica. B · 2017Article
- Transmission of HBV DNA Mediated by Ceramide-Triggered Extracellular Vesicles.Cellular and molecular gastroenterology and hepatology · 2017Article
- Investigation of a Novel Hepatitis B Virus Surface Antigen (HBsAg) Escape Mutant Affecting Immunogenicity.PloS one · 2017Article
- Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells.Journal of hepatology · 2016Article
- Hepatitis B virus receptors and molecular drug targets.Hepatology international · 2016Review
- Experimental models of hepatitis B and C - new insights and progress.Nature reviews. Gastroenterology & hepatology · 2016Review
- Detection and analysis of tupaia hepatocytes via mAbs against tupaia serum albumin.Experimental animals · 2016Article
- A Novel Hydrodynamic Injection Mouse Model of HBV Genotype C for the Study of HBV Biology and the Anti-Viral Activity of Lamivudine.Hepatitis monthly · 2016Article
- Article
- Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact.Digestive diseases and sciences · 2015Review
- Viral hepatitis: past and future of HBV and HDV.Cold Spring Harbor perspectives in medicine · 2015Review
- A novel mouse model for stable engraftment of a human immune system and human hepatocytes.PloS one · 2015Article
- Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages.PLoS pathogens · 2014Article
- The role of natural killer cells and CD8(+) T cells in hepatitis B virus infection.Frontiers in immunology · 2014Review
- Interleukin-22 as a molecular adjuvant facilitates IL-17-producing CD8+ T cell responses against a HBV DNA vaccine in mice.Human vaccines & immunotherapeutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver disease associated to persistent infection with the hepatitis B virus (HBV) continues to be a major health problem of global impact. In spite of the existence of an effective vaccine, approximately 360 million people are chronically infected worldwide, who are at high risk of developing liver cirrhosis and hepatocellular carcinoma. Although current therapeutic regimens can efficiently suppress viral replication, the unique replication strategies employed by HBV permit the virus to persist within the infected hepatocytes. As a consequence, relapse of viral activity is commonly observed after cessation of treatment with polymerase inhibitors. The narrow host range of HBV has hindered progresses in understanding specific steps of HBV replication and the development of more effective therapeutic strategies aiming at achieving sustained viral control and, eventually, virus eradication. This review will focus on summarizing recent advances obtained with well-established and more innovative experimental models, giving emphasis on the strength of the different systems as tools for elucidating distinct aspects of HBV persistence and for the development of new therapeutic approaches.
Indexed as
Identifiers
22898798What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.